Longboard Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	21.44	17.25	5.47	-0.06
Depreciation & Amortization	9.8	3.89	5.43	-
Other Amortization	-	0.02	-	-
Loss (Gain) From Sale of Assets	-0.01	-	0.17	-
Other Operating Activities	10.24	8.99	5.61	-
Change in Accounts Receivable	-31.48	5.48	-32.8	-
Change in Inventory	-37.9	-37.87	-5.09	-
Change in Accounts Payable	-1.59	9.89	3.58	-
Change in Other Net Operating Assets	-2.04	-9.71	-32.2	-0.12
Operating Cash Flow	-31.56	-2.06	-49.83	-0.18
Capital Expenditures	-36.75	-3.65	-6.75	-
Sale of Property, Plant & Equipment	0.03	-	2.46	-
Investment in Securities	-	-0.05	-	-
Other Investing Activities	-	0.54	-	-
Investing Cash Flow	-36.73	-3.16	-4.3	-
Long-Term Debt Repaid	-7.66	-0.12	-8.88	-
Net Debt Issued (Repaid)	-7.66	-0.12	-8.88	-
Issuance of Common Stock	55.68	-	79.33	0.4
Other Financing Activities	29.96	-4.77	0.09	-
Financing Cash Flow	77.98	-4.89	70.54	0.4
Miscellaneous Cash Flow Adjustments	-0	-0	0	-
Net Cash Flow	9.69	-10.11	16.41	0.22
Free Cash Flow	-68.31	-5.71	-56.58	-0.18
Free Cash Flow Margin	-22.04%	-2.35%	-44.58%	-
Free Cash Flow Per Share	-12.84	-1.40	-46.84	-
Cash Interest Paid	4.83	3.3	3.04	-
Cash Income Tax Paid	1.04	-	-	-
Levered Free Cash Flow	-107.7	-27.51	-87.5	-
Unlevered Free Cash Flow	-104.68	-25.45	-85.61	-
Change in Net Working Capital	98.17	42.02	91.31	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.